Cellular stress and coagulation factor production: when more is not necessarily better

• Published in: Journal of thrombosis and haemostasis 2023-12, Vol.21 (12), p.3329-3341
• Main Authors: Chen, Zhouji, Herzog, Roland W., Kaufman, Randal J.
• Format: Article
• Language: English
• Subjects: Animals; Blood Coagulation Factors - genetics; ER stress; factor VIII; Factor VIII - metabolism; gene therapy; Genetic Therapy; hemophilia A; Hemophilia A - genetics; Hemophilia A - metabolism; Hemophilia A - therapy; Hemophilia B - drug therapy; Hemophilia B - therapy; Humans; Mammals - genetics; Mammals - metabolism; unfolded protein response
• ISSN: 1538-7836; 1538-7836
• DOI: 10.1016/j.jtha.2023.10.005

Remarkably, it has been 40 years since the isolation of the 2 genes involved in hemophilia A (HA) and hemophilia B (HB), encoding clotting factor (F) VIII (FVIII) and FIX, respectively. Over the years, these advances led to the development of purified recombinant protein factors that are free of contaminating viruses from human pooled plasma for hemophilia treatments, reducing the morbidity and mortality previously associated with human plasma-derived clotting factors. These discoveries also paved the way for modified factors that have increased plasma half-lives. Importantly, more recent advances have led to the development and Food and Drug Administration approval of a hepatocyte-targeted, adeno-associated viral vector-mediated gene transfer approach for HA and HB. However, major concerns regarding the durability and safety of HA gene therapy remain to be resolved. Compared with FIX, FVIII is a much larger protein that is prone to misfolding and aggregation in the endoplasmic reticulum and is poorly secreted by the mammalian cells. Due to the constraint of the packaging capacity of adeno-associated viral vector, B-domain deleted FVIII rather than the full-length protein is used for HA gene therapy. Like full-length FVIII, B-domain deleted FVIII misfolds and is inefficiently secreted. Its expression in hepatocytes activates the cellular unfolded protein response, which is deleterious for hepatocyte function and survival and has the potential to drive hepatocellular carcinoma. This review is focused on our current understanding of factors limiting FVIII secretion and the potential pathophysiological consequences upon expression in hepatocytes.